MA47167A - Composés pyrazolopyrimidine et leurs procédés d'utilisation - Google Patents
Composés pyrazolopyrimidine et leurs procédés d'utilisationInfo
- Publication number
- MA47167A MA47167A MA047167A MA47167A MA47167A MA 47167 A MA47167 A MA 47167A MA 047167 A MA047167 A MA 047167A MA 47167 A MA47167 A MA 47167A MA 47167 A MA47167 A MA 47167A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- pyrazolopyrimidine compounds
- pyrazolopyrimidine
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016112932 | 2016-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47167A true MA47167A (fr) | 2019-11-06 |
Family
ID=61094385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047167A MA47167A (fr) | 2016-12-29 | 2017-12-22 | Composés pyrazolopyrimidine et leurs procédés d'utilisation |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11155557B2 (fr) |
| EP (1) | EP3562809B1 (fr) |
| JP (1) | JP6900491B2 (fr) |
| KR (1) | KR20190100337A (fr) |
| CN (1) | CN110114343B (fr) |
| AU (1) | AU2017385543A1 (fr) |
| BR (1) | BR112019013287A2 (fr) |
| CA (1) | CA3046435A1 (fr) |
| CL (1) | CL2019001694A1 (fr) |
| CO (1) | CO2019006220A2 (fr) |
| CR (1) | CR20190310A (fr) |
| IL (1) | IL267671A (fr) |
| MA (1) | MA47167A (fr) |
| MX (1) | MX2019007339A (fr) |
| PE (1) | PE20191236A1 (fr) |
| PH (1) | PH12019501022A1 (fr) |
| RU (1) | RU2019123319A (fr) |
| WO (1) | WO2018122212A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019123319A (ru) | 2016-12-29 | 2021-02-01 | Ф. Хоффманн-Ля Рош Аг | Пиразолопиримидины и способы их применения |
| AU2018274577A1 (en) | 2017-05-22 | 2019-10-10 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
| WO2019139714A1 (fr) * | 2018-01-15 | 2019-07-18 | Genentech, Inc. | Composés pyrazolopyrimidine utilisés en tant qu'inhibiteurs de jak |
| WO2020257145A1 (fr) | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Inhibiteurs de sulfone pyrazolopyrimidine de jak kinases et leurs utilisations |
| WO2020257142A1 (fr) * | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Inhibiteurs de pyrazolopyrimidine à substitution tétrazole de kinases jak et leurs utilisations |
| WO2020257143A1 (fr) * | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Inhibiteurs éther-aryl-pyrazolopyrimidine de kinases jak et leurs utilisations |
| WO2022175829A1 (fr) * | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Formulations et compositions topiques |
| WO2024052512A1 (fr) * | 2022-09-09 | 2024-03-14 | Chiesi Farmaceutici S.P.A. | Dérivés hétérocycliques comme inhibiteurs de janus kinase |
| WO2024052513A1 (fr) * | 2022-09-09 | 2024-03-14 | Chiesi Farmaceutici S.P.A. | Dérivés hétérocycliques comme inhibiteurs de janus kinase |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPH11508583A (ja) | 1995-07-06 | 1999-07-27 | ゼネカ・リミテッド | ペプチド系のフィブロネクチン阻害薬 |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (fr) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dérivés de purine pour le traitement de l'ischémie |
| ES2271365T3 (es) | 2001-12-20 | 2007-04-16 | Bayer Healthcare Ag | Derivados de 1,4-dihidro-1,4-difenilpiridina. |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| PE20110545A1 (es) | 2008-06-20 | 2011-08-18 | Genentech Inc | Compuestos de triazolopiridina como inhibidores de jak |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| EP3145929B1 (fr) | 2014-05-23 | 2021-01-13 | F. Hoffmann-La Roche AG | Composés 5-chloro -2-difluorométhoxyphényl pyrazolopyrimidine utilisés en tant qu'inhibiteurs de jak |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| WO2017140825A1 (fr) | 2016-02-18 | 2017-08-24 | F. Hoffmann-La Roche Ag | Composés thérapeutiques, leurs compositions et méthodes d'utilisation |
| NZ750267A (en) | 2016-06-29 | 2023-12-22 | Hanmi Pharm Ind Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| RU2019123319A (ru) | 2016-12-29 | 2021-02-01 | Ф. Хоффманн-Ля Рош Аг | Пиразолопиримидины и способы их применения |
-
2017
- 2017-12-22 RU RU2019123319A patent/RU2019123319A/ru not_active Application Discontinuation
- 2017-12-22 CA CA3046435A patent/CA3046435A1/fr not_active Abandoned
- 2017-12-22 CN CN201780081495.7A patent/CN110114343B/zh active Active
- 2017-12-22 BR BR112019013287A patent/BR112019013287A2/pt not_active Application Discontinuation
- 2017-12-22 EP EP17836033.5A patent/EP3562809B1/fr active Active
- 2017-12-22 WO PCT/EP2017/084569 patent/WO2018122212A1/fr unknown
- 2017-12-22 JP JP2019535901A patent/JP6900491B2/ja active Active
- 2017-12-22 MX MX2019007339A patent/MX2019007339A/es unknown
- 2017-12-22 PE PE2019001227A patent/PE20191236A1/es unknown
- 2017-12-22 CR CR20190310A patent/CR20190310A/es unknown
- 2017-12-22 MA MA047167A patent/MA47167A/fr unknown
- 2017-12-22 AU AU2017385543A patent/AU2017385543A1/en not_active Abandoned
- 2017-12-22 KR KR1020197022055A patent/KR20190100337A/ko not_active Application Discontinuation
-
2019
- 2019-05-08 PH PH12019501022A patent/PH12019501022A1/en unknown
- 2019-06-14 CO CONC2019/0006220A patent/CO2019006220A2/es unknown
- 2019-06-19 CL CL2019001694A patent/CL2019001694A1/es unknown
- 2019-06-25 US US16/452,058 patent/US11155557B2/en active Active
- 2019-06-26 IL IL267671A patent/IL267671A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3562809B1 (fr) | 2021-06-09 |
| JP2020503339A (ja) | 2020-01-30 |
| AU2017385543A1 (en) | 2019-05-23 |
| IL267671A (en) | 2019-08-29 |
| EP3562809A1 (fr) | 2019-11-06 |
| CO2019006220A2 (es) | 2019-06-28 |
| PH12019501022A1 (en) | 2019-12-16 |
| CN110114343B (zh) | 2022-09-06 |
| WO2018122212A1 (fr) | 2018-07-05 |
| CR20190310A (es) | 2019-08-21 |
| MX2019007339A (es) | 2019-09-06 |
| RU2019123319A3 (fr) | 2021-02-01 |
| US20190345165A1 (en) | 2019-11-14 |
| CN110114343A (zh) | 2019-08-09 |
| PE20191236A1 (es) | 2019-09-11 |
| CL2019001694A1 (es) | 2019-11-22 |
| CA3046435A1 (fr) | 2018-07-05 |
| US11155557B2 (en) | 2021-10-26 |
| JP6900491B2 (ja) | 2021-07-07 |
| KR20190100337A (ko) | 2019-08-28 |
| BR112019013287A2 (pt) | 2019-12-24 |
| RU2019123319A (ru) | 2021-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA47167A (fr) | Composés pyrazolopyrimidine et leurs procédés d'utilisation | |
| MA43827A (fr) | Composés di-nucléotides cycliques et leurs procédés d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA54252A (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA42302A (fr) | Lactames bicycliques et leurs méthodes d'utilisation | |
| MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
| MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
| MA41999A (fr) | Compositions d'acide obéticholique et procédés d'utilisation | |
| MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
| MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation | |
| MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci |